Literature DB >> 25204257

A study comparing the effectiveness of three warning labels on the package of driving-impairing medicines.

Bas Emich1, Liset van Dijk, Susana P Monteiro, Johan J de Gier.   

Abstract

BACKGROUND: Several medicines are known to potentially impair patients' driving fitness. Appropriate communication towards patients about this risk can be supported by the use of package warning labels.
OBJECTIVE: To compare the effectiveness of a standing practice yellow/black label-with written warning-with a newly developed rating model in communicating risk on driving-impairing medicines (DIMs). Furthermore, the added value of a side-text in the rating model was determined.
SETTING: Community pharmacies in the Netherlands.
METHOD: In a cross-sectional study, patients with a first dispensing of a DIM were asked by their community pharmacists (n = 38) to fill out a written questionnaire to compare each of the three warning labels. A 2 [yellow/black label vs. rating model (pair 1) and rating model with side-text vs. rating model without side-text (pair 2)] × 3 [category of driving-impairment: I = minor risk, II = moderate risk, III = severe risk] design was used. The category of driving-impairment varied per respondent, depending on the DIM the patient collected. MAIN OUTCOME MEASURE: (1) estimated level of driving risk valued by patients (2) intention to change driving behaviour after seeing the warning label.
RESULTS: An estimated number of 992 patients were approached. As 298 questionnaires were analysed, the net response rate was 30%. With the yellow/black label, respondents considered DIMs of all three categories of driving-impairment to equally impair driving fitness, while with the rating model the estimated risk was higher when the category referred to a higher level of driving-impairment. Addition of a side-text to the rating model resulted in a significantly higher estimated level of driving risk and a significant increase in intention to change driving behaviour. Only 8.0% of the patients using a category III DIM estimated the level of driving risk correctly when seeing the yellow/black label, while this was 26.7% for the rating model and 43.0% for the rating model with side-text.
CONCLUSION: The yellow/black label, which is standing practice in the Netherlands, is less effective in terms of estimated risk and intention to change driving behaviour, compared to a newly developed rating model. This model is even more effective when a side-text is added. Implementation of the rating model in clinical practice should be considered.

Entities:  

Mesh:

Year:  2014        PMID: 25204257     DOI: 10.1007/s11096-014-0010-2

Source DB:  PubMed          Journal:  Int J Clin Pharm


  23 in total

1.  Risk communication in the clinical consultation.

Authors:  Richard Thomson; Adrian Edwards; Jenny Grey
Journal:  Clin Med (Lond)       Date:  2005 Sep-Oct       Impact factor: 2.659

2.  The Spanish pictogram on medicines and driving: The population's comprehension of and attitudes towards its use on medication packaging.

Authors:  Inmaculada Fierro; Trinidad Gómez-Talegón; F Javier Alvarez
Journal:  Accid Anal Prev       Date:  2012-08-31

3.  How effective are pictograms in communicating risk about driving-impairing medicines?

Authors:  Susana P Monteiro; René Huiskes; Liset Van Dijk; Julia C M Van Weert; Johan J De Gier
Journal:  Traffic Inj Prev       Date:  2013       Impact factor: 1.491

4.  Road traffic crashes and prescribed methadone and buprenorphine: a French registry-based case-control study.

Authors:  Philippe Corsenac; Emmanuel Lagarde; Blandine Gadegbeku; Bernard Delorme; Aurore Tricotel; Anne Castot; Nicholas Moore; Pierre Philip; Bernard Laumon; Ludivine Orriols
Journal:  Drug Alcohol Depend       Date:  2011-11-21       Impact factor: 4.492

Review 5.  A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project.

Authors:  Silvia Ravera; Susana P Monteiro; Johan Jacob de Gier; Trudy van der Linden; Trinidad Gómez-Talegón; F Javier Alvarez
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

6.  Randomized controlled trial evaluating pictogram augmentation of HIV medication information.

Authors:  Kyle Wilby; Carlo A Marra; Jack H da Silva; Maja Grubisic; Stephanie Harvard; Larry D Lynd
Journal:  Ann Pharmacother       Date:  2011-10-25       Impact factor: 3.154

7.  Medicines and driving: evaluation of training and software support for patient counselling by pharmacists.

Authors:  Sara-Ann Legrand; Sofie Boets; Uta Meesmann; Alain G Verstraete
Journal:  Int J Clin Pharm       Date:  2012-06-08

8.  Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test.

Authors:  Joris C Verster; Dieuwke S Veldhuijzen; Alain Patat; Berend Olivier; Edmund R Volkerts
Journal:  Curr Drug Saf       Date:  2006-01

9.  Exploring doctor and patient views about risk communication and shared decision-making in the consultation.

Authors:  Ruth E Davis; Gina Dolan; Sue Thomas; Christine Atwell; Donna Mead; Sarah Nehammer; Laurie Moseley; Adrian Edwards; Glyn Elwyn
Journal:  Health Expect       Date:  2003-09       Impact factor: 3.377

10.  The development of COMRADE--a patient-based outcome measure to evaluate the effectiveness of risk communication and treatment decision making in consultations.

Authors:  Adrian Edwards; Glyn Elwyn; Kerry Hood; Michael Robling; Christine Atwell; Margaret Holmes-Rovner; Paul Kinnersley; Helen Houston; Ian Russell
Journal:  Patient Educ Couns       Date:  2003-07
View more
  5 in total

1.  Receipt of Warnings Regarding Potentially Impairing Prescription Medications and Associated Risk Perceptions in a National Sample of U.S. Drivers.

Authors:  Robin A Pollini; Geetha Waehrer; Tara Kelley-Baker
Journal:  J Stud Alcohol Drugs       Date:  2017-11       Impact factor: 2.582

2.  Factors influencing changes in medication-taking and driving behavior after warnings about prescription medications that prohibit driving: an online survey.

Authors:  Yasue Fukuda; Moemi Saito
Journal:  BMC Public Health       Date:  2022-05-21       Impact factor: 4.135

3.  Use of driving-impairing medicines by a Spanish population: a population-based registry study.

Authors:  Eduardo Gutierrez-Abejón; Francisco Herrera-Gómez; Paloma Criado-Espegel; F Javier Alvarez
Journal:  BMJ Open       Date:  2017-11-22       Impact factor: 2.692

Review 4.  A narrative review on do's and don'ts in prescription label writing - lessons for pharmacists.

Authors:  Nithushi R Samaranayake; Wasana Grsk Bandara; Chinthana Mga Manchanayake
Journal:  Integr Pharm Res Pract       Date:  2018-06-13

5.  People with insomnia: experiences with sedative hypnotics and risk perception.

Authors:  Janet M Y Cheung; Delwyn J Bartlett; Carol L Armour; Jason G Ellis; Bandana Saini
Journal:  Health Expect       Date:  2015-08-03       Impact factor: 3.377

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.